At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET
Palvella Therapeutics announced that the FDA has granted rolling review for its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations. The company remains on track to complete the NDA submission in the second half of 2026. This regulatory milestone accelerates the review timeline for a potential first-approved therapy in an indication with no current FDA-approved treatments, a significant catalyst for this clinical-stage biotech.
- FDA granted rolling review for QTORIN™ rapamycin NDA for microcystic lymphatic malformations.
- Palvella remains on track to complete NDA submission in the second half of 2026.
- QTORIN™ rapamycin has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA.
- No FDA-approved therapies currently exist for the estimated 30,000+ U.S. patients with microcystic LMs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access